Reimbursement Experts Say Trial Endpoints Must Fit Add-On Payment Criteria
This article was originally published in The Gray Sheet
Executive SummaryDevice firms intending to seek a new technology add-on payment for their technology should craft their pivotal clinical trial endpoints to meet CMS' substantial clinical improvement criteria, according to W.L. Gore associate Antoinette Sheen
You may also be interested in...
Draft policy moots crowdfunding for high-cost rare diseases alongside financial support for those "amenable to one-time treatment" but falls way short of some patient groups' expectations.
India’s Hilleman Laboratories says it’s aiming to develop an affordable vaccine that will target pregnant women in low- and middle-income countries to prevent Group B Streptococcus, a potentially fatal infection passed to babies during childbirth.